Mobile

A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys®...

Update Il y a 5 ans
Reference: EUCTR2008-008258-21

A Randomized, Double-blinded, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination with Pegasys® and Copegus® versus the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 or 4 Virus Infection

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To study the effects of dose and duration of the HCV polymerase inhibitor prodrug (RO5024048) in combination with PEG-IFN and RBV versus the currently approved combination of PEG-IFN and RBV (SOC) in treatment-naive patients with chronic hepatitis C genotype 1 and 4 virus infection.

Inclusion criteria

  • Chronic hepatitis C

Links